Sinovac Biotech Ltd.
SVA · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $448,269 | $1,492,761 | $19,374,904 | $510,624 |
| % Growth | -70% | -92.3% | 3,694.4% | – |
| Cost of Goods Sold | $181,516 | $684,456 | $1,072,221 | $67,180 |
| Gross Profit | $266,753 | $808,305 | $18,302,683 | $443,444 |
| % Margin | 59.5% | 54.1% | 94.5% | 86.8% |
| R&D Expenses | $344,515 | $442,108 | $155,040 | $48,760 |
| G&A Expenses | $466,324 | $823,543 | $591,167 | $176,534 |
| SG&A Expenses | $466,324 | $823,543 | $591,167 | $176,534 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2,638 | $0 | $0 | $496 |
| Operating Expenses | $813,477 | $1,269,159 | $748,449 | $227,637 |
| Operating Income | -$546,724 | -$466,067 | $17,553,257 | $215,644 |
| % Margin | -122% | -31.2% | 90.6% | 42.2% |
| Other Income/Exp. Net | $393,690 | $491,305 | $9,784 | $973 |
| Pre-Tax Income | -$153,034 | $25,238 | $17,563,041 | $216,617 |
| Tax Expense | $105,321 | -$62,893 | $3,104,130 | $31,438 |
| Net Income | -$99,918 | $113,866 | $8,467,480 | $110,369 |
| % Margin | -22.3% | 7.6% | 43.7% | 21.6% |
| EPS | -1.06 | 1.08 | 85.2 | 1.06 |
| % Growth | -198.1% | -98.7% | 7,937.7% | – |
| EPS Diluted | -1.06 | 1 | 74.27 | 0.97 |
| Weighted Avg Shares Out | 99,608 | 99,502 | 99,312 | 98,897 |
| Weighted Avg Shares Out Dil | 99,608 | 114,173 | 114,006 | 113,662 |
| Supplemental Information | – | – | – | – |
| Interest Income | $85,114 | $190,818 | $102,568 | $1,930 |
| Interest Expense | $2,260 | $1,264 | $2,836 | $1,453 |
| Depreciation & Amortization | $144,745 | $156,597 | $100,429 | $6,626 |
| EBITDA | -$6,029 | $183,099 | $17,652,709 | $221,763 |
| % Margin | -1.3% | 12.3% | 91.1% | 43.4% |